Skip to main content

Table 2 Detailed overview of treatment with biological agents in 28 flares of 13 pediatric patients

From: Scoping review of biological treatment of deficiency of interleukin-36 receptor antagonist (DITRA) in children and adolescents

Target Drug Dose Pustule cleareance (day) Clinical improvement number of patients/total number treated Clinical response type Concomitant systemic treatment Treatment duration (months) Reference
TNF-a ETA NA NA 1/1 PR MTX 4 [19]
0.4 mg/kg twice per wk NA 1/1 CR* NA 7 [15]
12.5 mg/wk 35 1/1 CR ACI 1 mg/kg/d 6 [10]
NA NA 0/1 NR ACI 7 [3]
0.8 mg/kg/wk NA 0/1 NR 3 [6]
ADA 20 mg /every 2 wk NA 0/1 NR NA NA [15]
NA NA 1/1 CR** NA 26 [8]
NA NA 0/1 NR NA 1 [3]
20 mg every wk 7 1/1 CR 8 Patient reported here
IFL 100 mg in 2 wk. interval, in total 2 infusions (3,3 mg/kg) 14 1/1 CR** - 0,5*** [28]
5 mg/kg NA 1/1 CR** NA 9 [8]
NA NA 1/1 CR NA 1 [26]
IL-1 ANA 4 mg/kg/d 7 1/1 CR 2 [31]
5 mg/kg/d NA 0/1 NR NA 3 [5]
100 mg/d NA 0/1 NR NA 3 days [8]
6 mg/kg/d NA 0/1 NR NA NA [19]
5 mg/kg/d NA 0/1 NR NA NA [10]
NA NA 0/2 NR NA 2/0,2 [3]
6 mg/kg/d Partial 1/1 PR 36 [6]
CAN 3 mg/kg/d every 8 wks NA 0/1 NR NA NA [5]
IL12/23 UST NA NA 1/1 CR* NA 31 [8]
Pat 1: 1.5 mg/kg every 2 mths
Pat 2: 1 mg/kg every 2 mths
NA “weeks” 2/2 CR CR IVIG- 155 [3]
0.75 mg/kg every 3mths NA 1/1 CR 12 [6]
IL-17 SEC 150 mg/wkly ervery 4 wks 1 1/1 CR MTX 5 mg/wk 12 [8]
75 mg/wk NA 1/1 CR** PRED 2.5 mg/d 2 [19]
150 mg mthly 14 1/1 CR** 8**** [15]
300 mg every 4 wks, initially 5 doses 300 mg wkly 2 1/1 CR** 6 [24]
  1. Abbr. ADA-adalimumab, ANA-anakinra, CANA-canakinumab, CR-complete response, ETA-etanercept, IFL-infliximab, MP-methylprednisolone, NA-not available, NR-no response, PRED-prednisolone, PR-partial response, SEC-Secukinumab, UST-ustekinumab, * secondary failure after 7 months, changed to SEC **mild relaps, *** 21 months of follow-up interval after cessation of treatment, **** 4 months of follow-up interval after cessation of treatment.